GSK agreed to acquire Rapt Therapeutics for $2.2 billion to obtain ozureprubart, a long‑acting anti‑IgE monoclonal antibody currently in a Phase IIb prophylactic trial for food allergy. The transaction gives GSK global rights outside China and accelerates its push into immunology and allergy therapeutics. Companies expect Phase IIb data in 2027 and plan Phase III studies thereafter. Ozureprubart is designed for infrequent dosing (every 8–12 weeks) versus existing anti‑IgE therapy, potentially expanding eligibility to patients with high IgE or body‑weight constraints. GSK framed the deal as a strategic fit with its allergy portfolio; Rapt shareholders will receive $58 per share at close. The acquisition could reshape competition with established IgE blockers such as Xolair (omalizumab).